Therapy for severe equine asthma - New product has been designed to allow medication to be inhaled deep into the lungs of horses suffering severe asthma.
A new product has been designed to allow medication to be inhaled deep into the lungs of horses suffering severe asthma.
Aservo EquiHaler, a ciclesonide inhalation solution from Boehringer Ingelheim, has been in development as a collaboration between the firm’s animal health and human pharma divisions. The latter’s Respimat inhaler technology, which uses the trademarked Soft Mist technology, has now been integrated into the Aservo EquiHaler, which will allow medication to be inhaled deep into an affected horse’s lungs.
Marc Laemmer, head of equine devision of Boehringer Ingelheim in the UK and Ireland, said: “It’s another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation. We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available.
The active ingredient, ciclesonide, is a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly seen with systemic corticosteroids.